Table 3 |
||||||||
|
Unadjusted associations between surfactant protein A (SFTPA1,SFTPA2) haplotypes and persistent cough or wheeze in the first year of life.a Unadjusted odds ratios (OR) and 95% confidence intervals (CI) are from ordered logistic regression models predicting symptom frequency. b (CT and MA, 1998 – 2000) |
||||||||
|
Allele, haplotypec |
Nucleotide/amino acidd |
Estimated Frequency Distributione% (95% CI) |
Persistent Cough OR (95% CI) |
Wheeze OR (95% CI) |
||||
|
|
||||||||
|
SFTPA1 |
aa 19 |
aa 50 |
aa 62 |
aa 133 |
aa 219 |
|||
|
|
||||||||
|
6A |
C/Ala |
C/Leu |
G |
G |
C/Arg |
6.1% (4.0 – 8.3) |
3.69 (1.71, 7.98) |
4.72 (2.20, 10.11) |
|
6A2 |
T/Val |
G/Val |
A |
A |
C/Arg |
54.0% (49.3 – 58.7) |
1.18 (0.63, 2.19) |
1.13 (0.60, 2.14) |
|
6A3 |
T/Val |
C/Leu |
A |
A |
C/Arg |
25.6% (21.6 – 29.6) |
0.81 (0.49, 1.36) |
0.83 (0.49, 1.40) |
|
6A4 |
T/Val |
C/Leu |
G |
A |
T/Trp |
6.2% (4.1 – 8.4) |
0.94 (0.44, 2.03) |
0.70 (0.31, 1.60) |
|
all others |
8% |
|||||||
|
SFTPA2 |
aa 9 |
aa 91 |
aa 140 |
aa 223 |
||||
|
|
||||||||
|
1A |
C/Thr |
C/Pro |
C |
C/Gln |
8.4% (6.0 – 10.8) |
1.53 (0.75, 3.14) |
1.30 (0.63, 2.71) |
|
|
1A0 |
A/Asn |
G/Ala |
C |
C/Gln |
54.2% (49.5 – 58.8) |
1.13 (0.60, 2.13) |
1.14 (0.59, 2.19) |
|
|
1A1 |
C/Thr |
G/Ala |
T |
A/Lys |
13.7% (10.7 – 16.7) |
0.82 (0.45, 1.48) |
0.87 (0.47, 1.58) |
|
|
1A2 |
C/Thr |
G/Ala |
C |
C/Gln |
10.2% (7.6 – 12.7) |
0.95 (0.49, 1.84) |
0.83 (0.42, 1.64) |
|
|
1A3 |
A/Asn |
G/Ala |
T |
A/Lys |
1.8% (0.7 – 2.9) |
0.45 (0.08, 2.48) |
0.55 (0.10, 3.06) |
|
|
1A5 |
C/Thr |
C/Pro |
T |
C/Gln |
4.6% (2.7 – 6.5) |
0.43 (0.15, 1.23) |
0.66 (0.24, 1.79) |
|
|
1A6 |
C/Thr |
G/Ala |
T |
C/Gln |
3.2% (1.7 – 4.7) |
1.41 (0.49, 4.05) |
1.54 (0.54, 4.39) |
|
|
all others |
4% |
|||||||
|
SFTPA Haplotype |
||||||||
|
6A/1A |
5.4% (3.2 – 7.2) |
3.20 (1.39, 7.36) |
3.25 (1.43, 7.37) |
|||||
|
6A2/1A0 |
49.0% (44.4 – 53.6) |
1.20 (0.66, 2.19) |
1.04 (0.57, 1.90) |
|||||
|
6A2/1A2 |
1.8% (0.6 – 2.9) |
1.43 (0.36, 5.70) |
0.26 (0.03, 1.99) |
|||||
|
6A2/1A3 |
1.0% (0.2 – 1.9) |
0.65 (0.10, 4.39) |
0.79 (0.11, 5.47) |
|||||
|
6A3/1A0 |
4.7% (2.8 – 6.6) |
1.16 (0.49, 2.74) |
0.92 (0.37, 2.31) |
|||||
|
6A3/1A1 |
11.3% (8.5 – 14.1) |
1.12 (0.60, 2.08) |
1.08 (0.57, 2.04) |
|||||
|
6A3/1A2 |
5.6% (3.6 – 7.6) |
0.93 (0.40, 2.16) |
0.92 (0.39, 2.17) |
|||||
|
6A3/1A6 |
1.7% (0.5 – 2.8) |
0.91 (0.21, 4.07) |
2.26 (0.55, 9.33) |
|||||
|
6A4/1A5 |
2.9% (1.4 – 4.4) |
0.28 (0.07, 1.07) |
0.30 (0.08, 1.20) |
|||||
|
6A4/1A6 |
1.8% (0.6 – 3.0) |
1.88 (0.49, 7.16) |
1.69 (0.44, 6.39) |
|||||
|
Others |
14.9% |
|||||||
|
|
||||||||
|
aAnalyses included infants with complete data for both SFTPA alleles and respiratory symptoms, i.e., for SFTPA1 and persistent cough (N = 203) or wheeze (N = 202); SFTPA2 and persistent cough (N = 205) or wheeze (N = 204); SFTPA and persistent cough (N = 201) or wheeze (N = 200). bSeparate ordered logistic regression analyses were performed for each outcome measure and each haplotype with all other haplotypes serving as the reference group in each model. All model results (ORs [95% CI]) include estimates of model variabillity due to ambiguity in allele haplotype assignment (see text). Number of days per year of symptoms were included in models as a 6-category variable, i.e., 0, 1–7, 8–14, 15–21, 22–28, > 28 days. Significant results (p < 0.05) are in bold-face type. c By convention, SFTPA1 allele haplotypes are denoted by 6An and SFTPA2 allele haplotypes by 1Am [17,21]. daa 62, aa 133 and aa 140 are silent. eEstimated frequency distribution of haplotypes (mean, 95% CI) for white infants. |
||||||||
|
Pettigrew et al. BMC Medical Genetics 2007 8:15 doi:10.1186/1471-2350-8-15 |
||||||||
